Highly expressed of BID indicates poor prognosis and mediates different tumor microenvironment characteristics in clear cell renal cell carcinoma

• Published in: Discover. Oncology Vol. 15; no. 1; p. 176
• Main Authors: Zeng, Jiayi, Ke, Chuangbo, Tian, Kaiwen, Nie, Jianru, Huang, Shaoming, Song, Xiaosong, Xian, Zhiyong
• Format: Journal Article
• Language: English
• Published: New York Springer US 20.05.2024; Springer Nature B.V; Springer
• Subjects: Apoptosis; BID; Cancer Research; Cancer therapies; Chemotherapy; Clear cell renal cell carcinoma; Datasets; Genomes; Immunotherapy; Internal Medicine; Kidney cancer; Lymphocytes; Medical prognosis; Medicine; Medicine & Public Health; Metastasis; Molecular Medicine; Mutation; Nomograms; Oncology; Prognosis; Radiotherapy; Signal transduction; Surgical Oncology; Tumor microenvironment; Tumorigenesis; Tumors; Clear cell renal cell carcinoma; Prognosis; Tumor microenvironment; BID
• DOI: 10.1007/s12672-024-01035-8
• ISSN: 2730-6011

Background Studies have found that BH3 interacting domain death agonist (BID) is closely related to the occurrence and development of many kinds of tumors. However, little attention has been paid to the situation of BID in clear cell renal cell carcinoma (ccRCC). So, our aim was to explore the effect of BID in ccRCC. Methods Survival analysis, ROC curve, correlation analysis and Cox regression analysis were executed to analyze the prognostic value and clinical correlation of BID in ccRCC. The risk prognosis model was constructed in the training cohort and further validated in the internal testing cohort, ICGC cohort, and GEO cohort. Transcriptome sequencing and immunohistochemical staining of clinical specimens were used to validate the results of bioinformatics analysis. The GSEA, ESTIMATE algorithm, CIBERSORT algorithm, ssGSEA, TIDE score, correlation and difference analysis were used to analyze the effects of BID on immune infiltration in tumor microenvironment (TME). Results BID was highly expressed in ccRCC tissues, which was verified by transcriptome sequencing and immunohistochemical staining of clinical specimens. Patients with high expression of BID had a worse prognosis. BID is an independent prognostic factor for ccRCC. The prognostic model based on BID can accurately predict the prognosis of patients in different cohorts. In addition, the expression levels of BID was closely related to immunomodulatory molecules such as PD-1, LAG3, and CTLA4. Enrichment analysis indicated that BID was significantly enriched in immune-related responses and cancer-related pathways. The change of BID expression mediates different characteristics of immune infiltration in TME. Conclusions BID is highly expressed in ccRCC, which is a reliable biomarker of ccRCC prognosis. It is closely related to TME, and may be a potential target for immunotherapy in patients with ccRCC.